- Home
- CPRX vs HTFL Comparison
CPRX vs HTFL Comparison
Compare CPRX & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPRX | HTFL |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2006 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CPRX | HTFL |
|---|---|---|
| Price | $22.66 | $30.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $32.60 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 1.4M | 601.8K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.94 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $578,196,000.00 | $161,881,000.00 |
| Revenue This Year | $16.59 | $34.51 |
| Revenue Next Year | $8.42 | $24.58 |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | 25.56 | ★ 85.70 |
| 52 Week Low | $19.05 | $25.75 |
| 52 Week High | $26.58 | $41.22 |
Technical Indicators
Market Signals| Indicator | CPRX | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | N/A |
| Support Level | $23.01 | N/A |
| Resistance Level | $23.92 | N/A |
| Average True Range (ATR) | 0.69 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 47.29 | 0.00 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About HTFL Heartflow Inc. Common Stock
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.